"The newest allegations about activities at Philidor raise additional questions about the company's business practices," Valeant CEO J. Michael Pearson, said in a statement. "We have lost confidence in Philidor's ability to continue to operate in a manner that is acceptable to Valeant and the patients and doctors we serve."